Results 31 to 40 of about 231,834 (240)

Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis

Biomarker Research
Myelofibrosis is characterized by aberrant JAK/STAT signaling, with approved therapy including the JAK inhibitor ruxolitinib. Preclinical evidence implicates BCL-2 family proteins in MF pathogenesis and therapeutic response.
Giacomo Coltro, Viola Videschi, Francesca Gesullo, Federica Violi, Manjola Balliu, Alessandro M. Vannucchi, Paola Guglielmelli   +6 more
doaj   +1 more source

Leishmania donovani induced increase in macrophage Bcl-2 favors parasite survival

Frontiers in Immunology, 2016
Members of the Bcl-2 family are major regulators of apoptosis in mammalian cells and hence infection-induced perturbations in their expression could result into elimination of the parasites or creation of a niche favoring survival. In this investigation,
Rajeev Kumar Pandey, Sanjana Mehrotra, Smriti Sharma, Ramachandra Subbaraya Gudde, Shyam Sundar, Chandrima Shaha   +5 more
doaj   +1 more source

Evaluation of Bcl-2 as a marker for chronic kidney disease prediction in cats

Frontiers in Veterinary Science, 2023
Chronic kidney disease (CKD) is a frequent condition in elderly cats. Bcl-2 is linked to kidney disease through the processes of apoptosis and fibrosis.
Pattiya Pila, Phongsakorn Chuammitri, Phongsakorn Chuammitri, Prapas Patchanee, Kidsadagon Pringproa, Kakanang Piyarungsri, Kakanang Piyarungsri   +6 more
doaj   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

IMMUNOHISTOCHEMICAL EXPRESSION OF p53 AND BCL-2 PROTEINS IN ADVANCED ESOPHAGEAL CANCER PATIENTS [PDF]

Acta Medica Iranica, 2005
The current challenges in the management of esophageal cancer are to obtain a better understanding of underlying molecular alterations to provide new treatment options. We studied the p53 and Bcl-2 protein expression in esophageal carcinomas to correlate
S. Arbabi Bidgoli, B. Minaee, M. H. Ghahremani, S. N. Ostad, M. Djamali-Zavarei E. Azizi   +4 more
doaj   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?

Cancer Management and Research, 2018
Bibi Kulsoom,1 Tahir Sultan Shamsi,1 Nasir Ali Afsar,2,3 Zahida Memon,4 Nikhat Ahmed,4 Syed Nazrul Hasnain5 1National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan; 2Jinnah Medical and Dental College, Karachi, Pakistan ...
Kulsoom B, Shamsi TS, Afsar NA, Memon Z, Ahmed N, Hasnain SN   +5 more
doaj  

Endothelium Expression of Bcl-2 Is Essential for Normal and Pathological Ocular Vascularization.

PLoS ONE, 2015
Bcl-2 is an anti-apoptotic protein with important roles in vascular homeostasis and angiogenesis. Mice globally lacking Bcl-2 (Bcl-2 -/-) are small in stature and succumb to renal failure shortly after weaning as a result of renal hypoplasia/cystic ...
Ismail S Zaitoun, Ryan P Johnson, Nasim Jamali, Reem Almomani, Shoujian Wang, Nader Sheibani, Christine M Sorenson   +6 more
doaj   +1 more source